Our data suggest that specific PPARα modulators (SPPARMs) that preferentially induce the expression of oxidative targets, rather than lipogenic or LD-associated targets, might be used therapeutically to reduce TAG deposition in the livers of NAFLD/NASH patients. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.